Literature DB >> 11964039

Pathology, diagnosis and pathogenesis of AA amyloidosis.

Christoph Röcken1, Ann Shakespeare1.   

Abstract

Amyloid is defined as a proteinaceous tissue deposit that shows a typical green birefringence in polarised light after staining with Congo red, the presence of non-branching linear fibrils of indefinite length with an approximate diameter of 10-12 nm and a distinct X-ray diffraction pattern consistent with Pauling's model of a cross-beta fibril. Approximately 45% of generalised amyloidoses are secondary or reactive (AA) amyloidosis. Among the causes of AA amyloidosis are rheumatic diseases, idiopathic diseases, inherited diseases, infectious diseases and malignant tumours. Recent decades have provided significant advances in our understanding of the pathology and pathogenesis of AA amyloidosis. Its pathogenesis is multifactorial involving many variables such as primary structure of the precursor protein, acute phase response, the presence of non-fibril proteins (e.g. amyloid P component, apolipoprotein E, glycosaminoglycans, proteoglycans and basement membrane proteins), receptors, lipid metabolism and proteases. Study of the pathogenesis of AA amyloidosis has provided many insights into the nature of conformational diseases, which may help in the understanding of other members of this particularly heterogeneous group of diseases, such as Alzheimer's disease and transmissible spongiform encephalopathies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964039     DOI: 10.1007/s00428-001-0582-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  56 in total

Review 1.  Micropurification techniques in the analysis of amyloid proteins.

Authors:  B Kaplan; S Shtrasburg; M Pras
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

2.  Cellular mechanism of fibril formation from serum amyloid A1 protein.

Authors:  Stephanie Claus; Katrin Meinhardt; Tobias Aumüller; Ioana Puscalau-Girtu; Julia Linder; Christian Haupt; Paul Walther; Tatiana Syrovets; Thomas Simmet; Marcus Fändrich
Journal:  EMBO Rep       Date:  2017-06-21       Impact factor: 8.807

3.  Mutagenic analysis of the nucleation propensity of oxidized Alzheimer's beta-amyloid peptide.

Authors:  Tony Christopeit; Peter Hortschansky; Volker Schroeckh; Karlheinz Gührs; Giorgia Zandomeneghi; Marcus Fändrich
Journal:  Protein Sci       Date:  2005-06-29       Impact factor: 6.725

4.  [Amyloid diagnostics in rheumatic diseases].

Authors:  C Röcken; J Ernst
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

Review 5.  [Diagnostics and therapy of AA amyloidosis].

Authors:  N Blank; H M Lorenz
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

6.  [Amyloidoses in the Berlin Museum of Medical History of the Charité].

Authors:  C Röcken; N Widulin; T Schnalke
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

7.  A young patient with recurrent respiratory tract infection and anasarca.

Authors:  Kosar Hussain; Niaz Ahmed Shaikh; Liza Thomas; Mahmoud M Marashi
Journal:  BMJ Case Rep       Date:  2013-11-11

Review 8.  Secondary intestinal amyloidosis presenting intractable hematochezia: a case report and literature review.

Authors:  So Hyun Kim; Jae Hwang Kim; Mi Jin Gu
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

9.  Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.

Authors:  Saipraveen Srinivasan; Sanket Patke; Yun Wang; Zhuqiu Ye; Jeffrey Litt; Sunit K Srivastava; Maria M Lopez; Dmitry Kurouski; Igor K Lednev; Ravi S Kane; Wilfredo Colón
Journal:  J Biol Chem       Date:  2012-12-05       Impact factor: 5.157

10.  Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.

Authors:  Serhan Piskinpasa; Hadim Akoglu; Eyup Koc; Fatma Dogru; Ezgi Yenigun Coskun; Didem Turgut; Nihal Ozkayar; Ramazan Ozturk; Ali Riza Odabas; Fatih Dede
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.